Name

BiGEN

Legal name

BiGEN Co., Ltd.

Website

https://bi-gen.com

Company type

Private

Founded year

2015

Operating status

Operating

Ownership category

akta.pro rank

Product category

Biotech Investment Services

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

akta.pro secondary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

• Biotech investment services
• Cell therapy investment
• Gene therapy ventures
• Pharmaceutical formulation services
• Biotech venture capital

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales

Revenue model

1. Equity Investment Returns: BiGEN generates returns through equity investments in promising biotech companies, participating in Series A, B, and C funding rounds. Returns are realized through strategic partnerships, capital appreciation, and successful clinical development of portfolio companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

BiGEN operates as a biotech investment company that identifies and evaluates promising cell and gene therapy technologies developed by biotech companies, executes equity capital investment in qualified companies (Series A through C rounds), and establishes cooperative relationships with partner companies for further business development. In parallel, BiGEN serves as the Asian representative for ProJect Pharmaceutics GmbH, connecting Asian biopharmaceutical developers with parenteral drug formulation services spanning biopharmaceuticals, proteins, peptides, ADCs, live virus vaccines, and cytotoxics.

Product overview

BiGEN is a biotech investment company that provides equity investment in promising biotech companies and strategic partnership services. The company operates through three main investment portfolio companies: Momotaro-gene (developing adenoviral vector-based gene therapy for solid cancer), JUNTEN BIO (developing cell therapy products for immunotolerance in transplant patients), and Noile-Immune Biotech (developing PRIME CAR-T technology for solid tumors). BiGEN also serves as the Asian representative for ProJect Pharmaceutics' pharmaceutical formulation services and partners with CDMO Binex for manufacturing support.

Differentiator

Problem solved

Functional benefit

Products and services

• Biotech Equity Investment Services Equity capital investment services targeting early- to mid-stage biotech companies developing CAR-T cell therapies, gene therapies using adenoviral vectors, and regenerative medicine, with active participation across Series A, B, and C funding rounds. The service includes deal identification, technology evaluation, investment execution, and ongoing strategic partnership facilitation.
• Asian Representation for ProJect Pharmaceutics Pharmaceutical Formulation Services Channel representation services connecting Asian biopharmaceutical developers with ProJect Pharmaceutics GmbH's specialized parenteral drug formulation services covering biopharmaceuticals, proteins, peptides, ADCs, live virus vaccines, cytotoxics, and small molecules, supported by scientific justification packages.
• Strategic Biotech Partnership Development Strategic partnership facilitation services supporting biotech portfolio companies in establishing cooperative relationships with partner companies and international collaborators for business development across cancer treatment, autoimmune disease, and organ transplantation indications.

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• ProJect Pharmaceutics GmbHcoreChannel Partner/ Reseller/ Distributor · 18 April 2018BiGEN acts as the Asian representative of ProJect Pharmaceutics GmbH, a pharmaceutical service provider specialized in formulation and process development for parenteral drug products. BiGEN obtained exclusive right to promote PJP's formulation service in the territory of Asia.
• Binex Co., Ltd.coreStrategic or Co-development PartnerBinex is a Contract Development and Manufacturing Organization located in South Korea, providing full range services from cell line development to GMP manufacturing for drug substance and drug product. Services cover cGMP manufacturing for IMPs and commercial products.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Korea Investment Partners: One of Korea's largest VC/PE firms with a substantial healthcare/life sciences portfolio. Comparable to BiGEN in mandate (Korean equity investment in growth-stage companies) but with significantly larger AUM, broader sector coverage, and deeper resources.
• SBI Investment: Japan's largest independent venture capital firm with dedicated biotech/CGT investment programs. Competes directly with BiGEN for Japanese biotech investments such as CAR-T and gene therapy platforms, and is a likely co-investor or rival on deals like Noile-Immune Biotech.
• Aju IB Investment: Korean venture capital and growth investment firm with active portfolio exposure to healthcare and biotech. Competes with BiGEN in Korea for biotech deal flow and frequently co-invests in the same Series A/B rounds.
• LB Investment: Korea-based venture capital and growth equity firm with a dedicated healthcare and biotech investment practice. Operates in the same Korean biotech VC market as BiGEN, providing equity capital, strategic support, and follow-on financing to similar-stage Korean and regional biotech companies.
• JAFCO: Pioneering Japanese VC firm with a long-standing healthcare and life sciences practice. Overlaps with BiGEN in targeting Japanese biotech Series A/B rounds and in providing follow-on capital and post-investment support to portfolio companies.
• JIC Capital: Japanese institutional investor focused on growth-stage companies including biotech. Comparable in Japanese market presence and growth-equity orientation to BiGEN, particularly in supporting biotech companies through late-stage financing rounds.
• Mirae Asset Venture Investment: Korean venture capital arm of Mirae Asset Financial Group with active investments in biotech and healthcare. Competes with BiGEN for early-stage biotech deal flow in Korea and frequently participates in the same Korean Series A/B financings.

Broad incumbents

• OrbiMed: Global healthcare-dedicated investment firm managing private equity, venture, and royalty funds across biotech and medtech. Overlaps with BiGEN in providing equity and structured capital to biotech companies but with vastly larger AUM and global reach.
• ARCH Venture Partners: US-based venture capital firm focused exclusively on early-stage biotech and life sciences. Comparable to BiGEN in vertical specialization (biotech-only investing) but operates at significantly larger scale across a global portfolio of next-generation therapeutics companies.
• MPM Capital: Biotech-focused venture capital firm investing across oncology, cell/gene therapy, and rare diseases. Comparable to BiGEN in pure-play biotech mandate, including exposure to CAR-T and cell therapy assets, though it operates at larger fund size and broader geographic scope.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BiGEN